Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831291 | 0.88 | POLB (0.43) | ALDH1A1L3MBTL1MCL1DHODHPTGS1 | |
| SCHEMBL831013 | 0.85 | KMO (0.45) | ALDH1A1L3MBTL1MCL1PTGS1PTGS2 | |
| SCHEMBL831055 | 0.80 | EPRS1 (0.45) | EPRS1ALDH1A1L3MBTL1MCL1KDM4E | |
| SCHEMBL831107 | 0.77 | MAPT (0.45) | ALDH1A1L3MBTL1PTGS1PTGS2KDM4E | |
| SCHEMBL8073401 | 0.76 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1PTGS1PTGS2RXRA | |
| SCHEMBL830022 | 0.76 | POLB (0.42) | ALDH1A1L3MBTL1DHODHKDM4ERXFP1 | |
| SCHEMBL839946 | 0.75 | MDM2 (0.40) | ALDH1A1L3MBTL1 | |
| SCHEMBL831302 | 0.75 | XDH (0.48) | ALDH1A1L3MBTL1DHODHXDHKDM4E | |
| SCHEMBL832431 | 0.75 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1DHODHPTGS1PTGS2 | |
| SCHEMBL832712 | 0.75 | MAPT (0.41) | ALDH1A1L3MBTL1DHODHKDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009033561-A1 | SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | SLC5A6, FABP3, NAPRT | EPRS1 2153/4885ALDH1A1 1238/4885L3MBTL1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.